Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell linesSilvia La Monica, Roberta Alfieri|Journal of Experimental & Clinical Cancer Research|2017Cited by 89
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSilvia La Monica, Roberta Alfieri|Journal of Experimental & Clinical Cancer Research|2019Cited by 70
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET AmplificationSilvia La Monica, Roberta Alfieri|PLoS ONE|2013Cited by 49
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to OsimertinibSilvia La Monica, Roberta Alfieri|Cancers|2020Cited by 39